Arbutus Biopharma Stock Price, News & Analysis (NASDAQ:ABUS)

$5.55 0.40 (7.77 %)
(As of 01/24/2018 01:57 AM ET)
Previous Close$5.15
Today's Range$5.05 - $5.55
52-Week Range$2.35 - $8.25
Volume317,100 shs
Average Volume202,780 shs
Market Capitalization$302.79 million
P/E Ratio-1.11
Dividend YieldN/A
Beta1.07

About Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ABUS
CUSIPN/A
Phone+1-604-4193200

Debt

Debt-to-Equity Ratio0.08%
Current Ratio11.03%
Quick Ratio11.03%

Price-To-Earnings

Trailing P/E Ratio-1.1122244488978
Forward P/E Ratio-4.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.50 million
Price / Sales203.69
Cash Flow$6.38 per share
Price / Cash0.87
Book Value$3.70 per share
Price / Book1.50

Profitability

Trailing EPS($4.99)
Net Income$-384,160,000.00
Net MarginsN/A
Return on Equity-34.98%
Return on Assets-24.76%

Miscellaneous

Employees122
Outstanding Shares55,050,000

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) posted its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.21. View Arbutus Biopharma's Earnings History.

When will Arbutus Biopharma make its next earnings announcement?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Monday, March, 19th 2018. View Earnings Estimates for Arbutus Biopharma.

Where is Arbutus Biopharma's stock going? Where will Arbutus Biopharma's stock price be in 2018?

6 Wall Street analysts have issued 12 month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $32.00. On average, they expect Arbutus Biopharma's stock price to reach $12.50 in the next year. View Analyst Ratings for Arbutus Biopharma.

What are Wall Street analysts saying about Arbutus Biopharma stock?

Here are some recent quotes from research analysts about Arbutus Biopharma stock:

  • 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (1/18/2018)
  • 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a increase in short interest in December. As of December 29th, there was short interest totalling 763,650 shares, an increase of 41.3% from the December 15th total of 540,515 shares. Based on an average daily volume of 183,159 shares, the short-interest ratio is currently 4.2 days. Currently, 2.2% of the company's shares are short sold.

Who are some of Arbutus Biopharma's key competitors?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:

  • Vivek Ramaswamy, Chairman of the Board (Age 31)
  • Mark J. Murray Ph.D., President, Chief Executive Officer, Director (Age 67)
  • Bruce G. Cousins, Chief Financial Officer, Executive Vice President (Age 55)
  • Elizabeth Howard, Executive Vice President, General Counsel (Age 62)
  • Peter Lutwyche Ph.D., Chief Technology Officer (Age 50)
  • Michael Joseph Sofia, Chief Scientific Officer (Age 57)
  • William Thomas Symonds III, Chief Development Officer, Director (Age 48)
  • Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets (Age 59)
  • Patrick T. Higgins, Chief Business Officer (Age 58)
  • Daniel D. Burgess, Director (Age 55)

How do I buy Arbutus Biopharma stock?

Shares of Arbutus Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of Arbutus Biopharma stock can currently be purchased for approximately $5.55.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $302.79 million and generates $1.50 million in revenue each year. The biopharmaceutical company earns $-384,160,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Arbutus Biopharma employs 122 workers across the globe.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 Glenlyon Pky, BURNABY, BC V5J 5J8, Canada. The biopharmaceutical company can be reached via phone at +1-604-4193200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (ABUS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arbutus Biopharma (NASDAQ:ABUS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.833.002.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.50$13.00$15.00$12.00
Price Target Upside: 140.38% upside116.67% upside98.68% upside247.83% upside

Arbutus Biopharma (NASDAQ:ABUS) Consensus Price Target History

Price Target History for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Chardan CapitalReiterated RatingBuyMediumView Rating Details
1/5/2018B. RileyInitiated CoverageBuy -> Buy$10.00MediumView Rating Details
11/7/2017Leerink SwannReiterated RatingMarket Perform$4.00 -> $5.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $13.00HighView Rating Details
9/20/2017WedbushReiterated RatingOutperform$9.00MediumView Rating Details
6/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$32.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

Arbutus Biopharma (NASDAQ:ABUS) Earnings History and Estimates Chart

Earnings by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ ABUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/19/2018($0.41)N/AView Earnings Details
11/2/2017Q3 2017($0.38)($0.17)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.28)ViewN/AView Earnings Details
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
3/21/2017Q4 2016($0.38)($0.38)ViewN/AView Earnings Details
11/3/2016Q3 2016($0.53)($0.31)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.35)($0.35)ViewN/AView Earnings Details
5/4/2016Q1 2016($0.37)($0.31)ViewN/AView Earnings Details
3/9/2016Q4 2015($0.39)$0.31ViewN/AView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
5/6/2015Q1 2015($0.39)($0.40)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
5/14/2014Q1 2014$0.40($0.22)ViewN/AView Earnings Details
3/6/2014Q4 2013($0.02)($0.07)ViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
11/13/2013Q3 2013($0.03)($0.24)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.21)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.14)($0.18)ViewN/AView Earnings Details
3/27/2013Q4 2012($0.07)($0.38)ViewN/AView Earnings Details
12/18/2012Q3 2012($0.07)($0.12)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.16)($0.19)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.17)($0.25)ViewN/AView Earnings Details
3/27/2012Q4 2011$0.20($0.16)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.30)($0.12)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.31)($0.35)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.36)($0.31)ViewN/AView Earnings Details
3/17/2010Q4 2009($0.05)ViewN/AView Earnings Details
3/24/2009Q4 2008($0.06)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.11)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.14)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.02)ViewN/AView Earnings Details
3/31/2008Q4 2007$0.01ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Arbutus Biopharma (NASDAQ:ABUS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.38)($0.36)($0.37)
Q2 20182($0.39)($0.36)($0.38)
Q3 20182($0.40)($0.37)($0.39)
Q4 20182($0.41)($0.38)($0.40)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma (NASDAQ:ABUS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Arbutus Biopharma (NASDAQ ABUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 59.99%
Insider Trades by Quarter for Arbutus Biopharma (NASDAQ:ABUS)
Insider Trades by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ ABUS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2017Michael J SofiaInsiderSell10,000$8.00$80,000.00View SEC Filing  
8/15/2017Michael J SofiaInsiderSell30,000$3.70$111,000.001,563,403View SEC Filing  
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.001,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arbutus Biopharma (NASDAQ ABUS) News Headlines

Source:
DateHeadline
Arbutus Biopharma Corp (ABUS) Receives Consensus Rating of "Hold" from AnalystsArbutus Biopharma Corp (ABUS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 20 at 1:40 PM
Arbutus Biopharma (ABUS) Given Buy Rating at Chardan CapitalArbutus Biopharma (ABUS) Given Buy Rating at Chardan Capital
www.americanbankingnews.com - January 20 at 6:28 AM
Zacks Investment Research Downgrades Arbutus Biopharma (ABUS) to SellZacks Investment Research Downgrades Arbutus Biopharma (ABUS) to Sell
www.americanbankingnews.com - January 18 at 4:46 PM
Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant SciencesArbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences
finance.yahoo.com - January 16 at 11:31 AM
Arbutus Biopharma Corp (ABUS) Short Interest UpdateArbutus Biopharma Corp (ABUS) Short Interest Update
www.americanbankingnews.com - January 14 at 2:32 AM
Arbutus Biopharma (ABUS) Coverage Initiated at B. RileyArbutus Biopharma (ABUS) Coverage Initiated at B. Riley
www.americanbankingnews.com - January 6 at 11:50 PM
Arbutus Biopharma Corp (ABUS) Given Consensus Recommendation of "Hold" by BrokeragesArbutus Biopharma Corp (ABUS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 26 at 2:08 PM
Albany Molecular Research (AMRI) and Arbutus Biopharma (ABUS) Head-To-Head ReviewAlbany Molecular Research (AMRI) and Arbutus Biopharma (ABUS) Head-To-Head Review
www.americanbankingnews.com - December 26 at 5:48 AM
Arbutus Biopharma (ABUS) Upgraded to "Sell" by BidaskClubArbutus Biopharma (ABUS) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - December 23 at 5:04 PM
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp - Seeking AlphaRisk-Adjusted Net Present Value For Arbutus Biopharma Corp - Seeking Alpha
seekingalpha.com - December 21 at 11:30 AM
Arbutus Biopharma (ABUS) Stock Rating Lowered by BidaskClubArbutus Biopharma (ABUS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 17 at 7:44 AM
ValuEngine Lowers Arbutus Biopharma (ABUS) to Strong SellValuEngine Lowers Arbutus Biopharma (ABUS) to Strong Sell
www.americanbankingnews.com - December 16 at 4:22 PM
BidaskClub Downgrades Arbutus Biopharma (ABUS) to SellBidaskClub Downgrades Arbutus Biopharma (ABUS) to Sell
www.americanbankingnews.com - December 2 at 4:02 PM
Arbutus Biopharma Corporation (ABUS) Receives Consensus Recommendation of "Buy" from AnalystsArbutus Biopharma Corporation (ABUS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 7:49 PM
Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 28, 2017Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 28, 2017
finance.yahoo.com - November 28 at 8:48 AM
Arbutus Announces Presentations at HepDART 2017 - GlobeNewswire (press release)Arbutus Announces Presentations at HepDART 2017 - GlobeNewswire (press release)
globenewswire.com - November 27 at 3:21 PM
Arbutus Announces Presentations at HepDART 2017Arbutus Announces Presentations at HepDART 2017
finance.yahoo.com - November 27 at 3:21 PM
Arbutus LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to US Food and Drug ... - GlobeNewswire (press release)Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to US Food and Drug ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 8:25 AM
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for PatisiranArbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
finance.yahoo.com - November 16 at 3:35 PM
Arbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from EMAArbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from EMA
www.streetinsider.com - November 14 at 3:24 AM
Arbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from ... - StreetInsider.comArbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from ... - StreetInsider.com
www.streetinsider.com - November 13 at 10:23 PM
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
finance.yahoo.com - November 13 at 10:23 PM
Equities Analysts Issue Forecasts for Arbutus Biopharma Corporations FY2017 Earnings (ABUS)Equities Analysts Issue Forecasts for Arbutus Biopharma Corporation's FY2017 Earnings (ABUS)
www.americanbankingnews.com - November 9 at 8:45 AM
Arbutus Biopharma Corporation (ABUS) Upgraded by Zacks Investment Research to HoldArbutus Biopharma Corporation (ABUS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - November 7 at 11:50 PM
Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 4:49 PM
Arbutus Biopharma Corporation (ABUS) Earns "Market Perform" Rating from Leerink SwannArbutus Biopharma Corporation (ABUS) Earns "Market Perform" Rating from Leerink Swann
www.americanbankingnews.com - November 7 at 11:32 AM
Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 6, 2017Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 6, 2017
finance.yahoo.com - November 6 at 4:06 PM
Arbutus Biopharma Corporation (ABUS) Given Average Rating of "Buy" by BrokeragesArbutus Biopharma Corporation (ABUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 3:42 PM
Arbutus Biopharma Corporation (ABUS) Expected to Post Quarterly Sales of $790,000.00Arbutus Biopharma Corporation (ABUS) Expected to Post Quarterly Sales of $790,000.00
www.americanbankingnews.com - November 6 at 6:04 AM
Arbutus Biopharmas (ABUS) CEO Mark Murray on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaArbutus Biopharma's (ABUS) CEO Mark Murray on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 5 at 3:26 PM
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 3:14 PM
Edited Transcript of ABUS earnings conference call or presentation 2-Nov-17 8:15pm GMTEdited Transcript of ABUS earnings conference call or presentation 2-Nov-17 8:15pm GMT
finance.yahoo.com - November 3 at 10:22 AM
Arbutus Announces Corporate Update and Third Quarter 2017 Financial ResultsArbutus Announces Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 8:28 PM
Arbutus Biopharma Corporation to Host Earnings CallArbutus Biopharma Corporation to Host Earnings Call
finance.yahoo.com - November 2 at 3:25 PM
Should You Buy Arbutus Biopharma Corporation (ABUS)?Should You Buy Arbutus Biopharma Corporation (ABUS)?
finance.yahoo.com - November 1 at 3:24 PM
Arbutus Biopharma Corp. – Value Analysis (NASDAQ:ABUS) : October 27, 2017Arbutus Biopharma Corp. – Value Analysis (NASDAQ:ABUS) : October 27, 2017
finance.yahoo.com - October 27 at 5:31 PM
Arbutus Biopharma Corp. breached its 50 day moving average in a Bearish Manner : ABUS-US : October 26, 2017Arbutus Biopharma Corp. breached its 50 day moving average in a Bearish Manner : ABUS-US : October 26, 2017
finance.yahoo.com - October 26 at 11:37 AM
Aptose Biosciences (APTO) versus Arbutus Biopharma Corporation (ABUS) Financial ReviewAptose Biosciences (APTO) versus Arbutus Biopharma Corporation (ABUS) Financial Review
www.americanbankingnews.com - October 25 at 8:37 AM
Arbutus Biopharma Corporation (ABUS) Scheduled to Post Earnings on WednesdayArbutus Biopharma Corporation (ABUS) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:30 AM
Arbutus Presents HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)Arbutus Presents HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)
globenewswire.com - October 24 at 8:24 PM
Arbutus Presents HBV Data at 2017 AASLD Liver MeetingArbutus Presents HBV Data at 2017 AASLD Liver Meeting
feeds.benzinga.com - October 24 at 8:25 AM
Arbutus out-licenses LNP technology to Gritstone Oncology - Seeking AlphaArbutus out-licenses LNP technology to Gritstone Oncology - Seeking Alpha
seekingalpha.com - October 18 at 3:42 PM
Arbutus Biopharma (ABUS) and Gritstone Oncology Reports LNP ... - StreetInsider.comArbutus Biopharma (ABUS) and Gritstone Oncology Reports LNP ... - StreetInsider.com
www.streetinsider.com - October 18 at 3:42 PM
Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer PatientsGritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
finance.yahoo.com - October 18 at 3:42 PM
Bucks biopharm firm signs licensing deal with California onco-immunology companyBucks biopharm firm signs licensing deal with California onco-immunology company
finance.yahoo.com - October 18 at 3:42 PM
Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences - GlobeNewswire (press release)Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences - GlobeNewswire (press release)
globenewswire.com - October 16 at 3:32 PM
Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant SciencesArbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 16 at 3:32 PM
Contrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)Contrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)
www.americanbankingnews.com - October 16 at 10:58 AM
Arbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.38 Per ShareArbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - October 15 at 2:24 PM
Arbutus Biopharma Corporation (ABUS) Receives Consensus Rating of "Buy" from BrokeragesArbutus Biopharma Corporation (ABUS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 4:46 PM

SEC Filings

Arbutus Biopharma (NASDAQ:ABUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arbutus Biopharma (NASDAQ:ABUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arbutus Biopharma (NASDAQ ABUS) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.